Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

HYDERABAD: A surge in the unsupervised use of popular diabetes and weight-loss drugs in Hyderabad has raised alarm among doctors, who warn that social media trends and peer influence are pushing many ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...

Muriel, from the Auxiliary of Social Life, works at the home of Mr. T, who has multiple sclerosis, in Pas de Calais, France, on June 11, 2023. (Astier / BSIP via AFP) (CN) — For people living with ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines. Dr. Reddy’s, an Indian generic ...

The U.S. Food and Drug Administration announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to cheaper ...